Santhera cleared for visual impairment treatment Raxone in IsraelAugust 31, 2017
The Swiss drugmaker Santhera Pharmaceuticals has been cleared in Israel for Raxone (idebenone) for visual impairment in adolescents and older, with Leber’s hereditary optic neuropathy (LHON).
The clearance from the Ministry of Health Israel, the first approval for Raxone in LHON outside Europe, was announced Thursday. After the European Commission’s marketing authorization for Raxone, the first approved treatment in LHON and the first approved treatment for a mitochondrial disease, the Ministry of Health Israel gave Raxone a marketing authorization for the treatment of visual impairment in adolescent and adult patients with LHON.
Giovanni Stropoli, Chief Commercial Officer Europe & ROW at Santhera, said that the company has signed a strategic deal with Megapharm, a leading Israeli private pharma marketing company, who is committed to making Raxone available to patients with LHON in Israel.
Image: Bottles containing 180 tablets of Raxone (idebenone 150 mg). Image: Santhera